IllinoisVENTURES portfolio company, Actuate Therapeutics, Inc., raised $21.7M in a Series B financing round that will fund the expansion of the company’s ongoing Phase I/II 1801 clinical trial and development programs. Actuate is a clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutic agents for patients with cancer or inflammatory diseases.
“We are quickly advancing the 1801 clinical trial of 9-ING-41 in adult cancer patients in the US. The financing allows us to expand the 1801 clinical trial out to our world-leading oncology research institution network in the US and Europe, to initiate Investigator Initiated Trials being developed with our physician/scientist collaborators, and to advance our pediatric neuroblastoma program” noted Daniel Schmitt, President and CEO of Actuate in a press release issued by Cision.
To learn more about Actuate, click here.